XML 223 R166.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [1] | $ 53,647 |  | $ 52,546 | $ 52,824
Innovative Health and Essential Health [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 53,647 |  | 52,546 | 52,824
Innovative Health and Essential Health [Member] | Lyrica [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [2] | 4,970 |  | 5,065 | 4,966
Innovative Health and Essential Health [Member] | Viagra [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [3] | 636 |  | 1,204 | 1,564
Innovative Health and Essential Health [Member] | Alliance Biopharmaceuticals [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 3,838 | [4] | 2,927 | 1,746
Innovative Health Business [Member] | Innovative Health Segment [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [5] | 33,426 |  | 31,422 | 29,197
Essential Health Business [Member] | Essential Health Segment [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [6] | 20,221 |  | 21,124 | 23,627
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 9,996 |  | 9,684 | 8,858
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Lyrica [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [2] | 4,622 |  | 4,511 | 4,165
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Eliquis [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 3,434 |  | 2,523 | 1,713
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Chantix Champix [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,085 |  | 997 | 842
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | BMP2 [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 279 |  | 261 | 251
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Toviaz [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 271 |  | 257 | 258
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Viagra [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [3] | 0 |  | 823 | 1,181
Internal Medicine [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | All Other Internal Medicine [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 306 |  | 312 | 447
Vaccines [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 6,332 |  | 6,001 | 6,071
Vaccines [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Prevenar Family [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 5,802 |  | 5,601 | 5,718
Vaccines [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | FSME-IMMUN/TicoVac [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 184 |  | 134 | 114
Vaccines [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Trumenba [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 116 |  | 88 | 84
Vaccines [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Other Vaccines Products [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 230 |  | 177 | 155
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 7,202 |  | 6,056 | 4,563
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Ibrance [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 4,118 |  | 3,126 | 2,135
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Sutent [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,049 |  | 1,081 | 1,095
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Xtandi Alliance [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 699 |  | 590 | 140
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Xalkori [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 524 |  | 594 | 561
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Inlyta [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 298 |  | 339 | 401
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Bosulif [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 296 |  | 233 | 167
Oncology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Other Oncology Products [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 219 |  | 93 | 63
Inflammation and Immunology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 4,080 |  | 3,968 | 3,928
Inflammation and Immunology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Enbrel [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 2,112 |  | 2,452 | 2,909
Inflammation and Immunology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Xeljanz [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,774 |  | 1,345 | 927
Inflammation and Immunology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Eucrisa [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 147 |  | 67 | 0
Inflammation and Immunology [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | All Other Inflammation and Immunology Products [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 46 |  | 103 | 93
Rare Disease [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 2,211 |  | 2,240 | 2,369
Rare Disease [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Genotropin [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 558 |  | 532 | 579
Rare Disease [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | BeneFIX [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 554 |  | 604 | 712
Rare Disease [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | ReFacto AF Xyntha [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 514 |  | 551 | 554
Rare Disease [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | Somavert [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 267 |  | 254 | 232
Rare Disease [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] | All Other Rare Disease Products [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 318 |  | 300 | 292
Consumer Healthcare [Member] | Innovative Health Business [Member] | Innovative Health Segment [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 3,605 |  | 3,472 | 3,407
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [7] | 10,540 |  | 10,894 | 11,197
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Lipitor [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 2,062 |  | 1,915 | 1,758
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Norvasc [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,024 |  | 926 | 962
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Premarin Family [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 832 |  | 977 | 1,017
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Xalatan Xalacom [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 318 |  | 335 | 363
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Effexor [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 311 |  | 297 | 278
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Epi Pen [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 303 |  | 290 | 386
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Zoloft [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 298 |  | 291 | 304
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Zithromax Zmax [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 290 |  | 270 | 272
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Xanax/Xanax XR [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 223 |  | 225 | 222
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Sildenafil Citrate [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 56 |  | 56 | 0
Legacy Established Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Other Legacy Established Products [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 4,822 |  | 5,313 | 5,636
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [8] | 5,214 |  | 5,673 | 6,014
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Sulperazon [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 613 |  | 471 | 396
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Medrol [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 427 |  | 483 | 450
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Fragmin [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 293 |  | 306 | 318
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Tygacil [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 249 |  | 260 | 274
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Zosyn / Tazocin [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 229 |  | 194 | 146
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Precedex [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 213 |  | 243 | 264
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | All Other Sterile Injectable Pharmaceuticals [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 3,191 |  | 3,715 | 4,166
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [9] | 2,944 |  | 3,223 | 4,220
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Lyrica [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [2] | 347 |  | 553 | 801
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Viagra [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [3] | 636 |  | 382 | 383
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Celebrex [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 686 |  | 775 | 733
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Vfend [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 392 |  | 421 | 590
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Zyvox [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 236 |  | 281 | 421
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Revatio [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 227 |  | 252 | 285
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Pristiq [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 206 |  | 303 | 732
Peri-LOE Products [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | All Other Peri-LOE Products [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 213 |  | 257 | 276
Biosimilars [Member] | Essential Health Business [Member] | Essential Health Segment [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [10] | 769 |  | 531 | 319
Biosimilars [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | Inflectra/Remsima [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 642 |  | 419 | 192
Biosimilars [Member] | Essential Health Business [Member] | Essential Health Segment [Member] | All Other Biosimilars [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 127 |  | 112 | 127
CentreOne [Member] | Essential Health Business [Member] | Essential Health Segment [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [11] | 755 |  | 706 | 718
Hospira Infusion Systems [Member] | Essential Health Business [Member] | Essential Health Segment [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | $ 0 |  | $ 97 | $ 1,158
[1] | Amounts may not add due to rounding.
[2] | Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH.
[3] | Viagra lost exclusivity in the U.S. in December 2017. In 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, were reported in EH (which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore, in 2018, total Viagra worldwide revenues were reported in EH. Total Viagra revenues in 2017 and 2016 represented the aggregate of worldwide revenues from Viagra IH and Viagra EH.
[4] | Substantially all relates to amounts earned from our partners under co-promotion agreements. The increases in 2018 and 2017 reflect increases in alliance revenues from Eliquis and Xtandi.
[5] | The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare. Through December 31, 2016, includes Duavive/Duavee and Viviant (recorded in All other Internal Medicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order to align these products with our management of the women’s health portfolio within EH.
[6] | The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017).
[7] | Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.Effective January 1, 2017, All other LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these products with our management of the women’s health portfolio within EH. See note (a) above.
[8] | Sterile Injectable Pharmaceuticals includes branded and generic injectables (excluding Peri-LOE Products). In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.
[9] | Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products primarily include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; and worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra; and in 2018, Viagra revenues for all countries (and Viagra revenues for all countries other than the U.S. and Canada in 2017 and 2016), see note (c) above.
[10] | Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and in the U.S. and Retacrit (biosimilar epoetin zeta) in the U.S. and certain European and Africa/Middle Eastern markets.
[11] | Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthandEssentialHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_LyricaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ViagraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AllianceBiopharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_DistinctBusinessAxis=pfe_InnovativeHealthBusinessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_DistinctBusinessAxis=pfe_EssentialHealthBusinessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_InnovativeProductsCategoryAxis=pfe_InternalMedicineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_EliquisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ChantixChampixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_BMP2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ToviazMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AllOtherInternalMedicineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_InnovativeProductsCategoryAxis=pfe_VaccinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PrevnarPrevenarFamilyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_FSMEIMMUNTicoVacMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_TrumenbaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_OtherVaccinesProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_InnovativeProductsCategoryAxis=pfe_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_IbranceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_SutentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_XtandiAllianceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_XalkoriMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_InlytaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_BosulifMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_OtherOncologyProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_InnovativeProductsCategoryAxis=pfe_InflammationandImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_EnbrelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_XeljanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_EucrisaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AllOtherInflammationandImmunologyProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_InnovativeProductsCategoryAxis=pfe_RareDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_GenotropinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_BeneFIXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ReFactoAfXynthaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_SomavertMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AllOtherRareDiseaseProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_InnovativeProductsCategoryAxis=pfe_ConsumerHealthcareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_EssentialHealthProductCategoryAxis=pfe_LegacyEstablishedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_LipitorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_NorvascMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PremarinFamilyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_XalatanXalacomMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_EffexorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_EpiPenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ZoloftMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ZithromaxZmaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_XanaxXanaxXRMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_SildenafilCitrateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_OtherLegacyEstablishedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_EssentialHealthProductCategoryAxis=pfe_SterileInjectablePharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_SulperazonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_MedrolMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_FragminMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_TygacilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ZosynTazocinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PrecedexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AllOtherSterileInjectablePharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_EssentialHealthProductCategoryAxis=pfe_PeriLOEProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_CelebrexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_VfendMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ZyvoxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_RevatioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PristiqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AllOtherPeriLOEProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_EssentialHealthProductCategoryAxis=pfe_BiosimilarsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_InflectraRemsimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AllOtherBiosimilarsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_EssentialHealthProductCategoryAxis=pfe_CentreOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_EssentialHealthProductCategoryAxis=pfe_HospiraInfusionSystemsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |